Phaseline

Companies › VIVUS

VIVUS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VI-0609
Alkylating agent; nitrosourea
PARP1Phase 2LymphomaMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06915246VI-0609Phase 2LymphomaOncologyMar 2027

Targets

PARP1 (1)

Companies with the same targets

AstraZeneca Eikon Therapeutics Haisco Pharmaceutical Group Hangzhou SynRx Therapeutics Biomedical Technology Merck & Co. (MSD) Nerviano Medical Sciences Pfizer Johnson & Johnson (Janssen) Jiangsu Hansoh Pharmaceutical Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Impact Therapeutics Allarity Therapeutics Shanghai Guangsheng Biopharmaceutical Panbela Therapeutics Apollomics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.